Andrew Elder
Deputy Managing Partner
Joined 2005
Overview
A former neurosurgeon, Andrew focuses on medical technologies and technology-enabled services to the healthcare and life-science sectors.He has invested in sectors ranging from digital health, diagnostics and imaging, machine learning applications and therapeutics, including cell and gene therapies. Andrew leads partnerships with universities including UCL and is a Member of Investment Committee at the British Business Bank.
Prior to joining AlbionVC he specialised in healthcare strategy at the Boston Consulting Group (BCG). He holds degrees in Medicine and Surgery from the University of Cambridge and is a Fellow of the Royal College of Surgeons.
Personal
Andrew has recently exited from a high-pressure investment into his own health – his pursuit of a series of endurance sports. The father-of-three says he is now most at peace when exercising a little more gently. He can often be found on a board or boat, on a bike, or half-way up a mountain. He also spends time helping others via a range of mentoring and charitable roles.
Andrew currently supports Aridhia, CS Genetics, Flok Health and Healios. He had previously led investments into multiple successful healthtech companies, including Dexela (Perkin Elmer), Exco Intouch, Abcodia (AIM), and MyMeds &Me.
From Stephen Grellet, a 19thCentury Quaker missionary:
ANDREW ELDER, DEPUTY MANAGING PARTNER
“ I shall pass through this world but once. Any good therefore that I can do or any kindness that I can show to any human being, let me do it now. Let me not defer or neglect it, for I shall not pass this way again.”
Featured content
trumpet launches Copilot, an AI-powered AI-powered buyer engagement at scale
Built on five years of insights from 15,000+ revenue teams, Copilot researches accounts, analyses deals and creates personalised buyer workspaces in seconds.
Commercialising university research: insights from AlbionVC’s Dave Grimm
In this Infinite Frontiers conversation, AlbionVC Partner Dave Grimm explores why Europe lags in commercialising research, how deep tech spinouts can scale from lab to market, and what founders, investors and universities must do to build the next generation of breakthrough companies.
